Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 1/20 | 0.56 |
| ▸ | PPARA | Q07869 | 1/20 | 0.56 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.48 |
| ▸ | ITGB7 | P26010 | 1/20 | 0.48 |
| ▸ | CTSS | P25774 | 6/20 | 0.47 |
| ▸ | CTSK | P43235 | 5/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | CTSL | P07711 | 1/20 | 0.46 |
| ▸ | CTSB | P07858 | 1/20 | 0.46 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.44 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.44 |
| ▸ | ACE | P12821 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1620272 | 1.00 | PPARG (0.56) | PPARGPPARAITGA4ITGB7CTSS | |
| SCHEMBL13913371 | 1.00 | PPARG (0.56) | PPARGPPARAITGA4ITGB7CTSS | |
| SCHEMBL30912525 | 0.92 | PPARG (0.59) | PPARGPPARAITGA4ITGB7CTSS | |
| SCHEMBL3784750 | 0.92 | PPARG (0.59) | PPARGPPARAITGA4ITGB7CTSS | |
| SCHEMBL6674404 | 0.92 | PPARG (0.59) | PPARGPPARAITGA4ITGB7CTSS | |
| SCHEMBL19212613 | 0.91 | PPARG (0.58) | PPARGPPARAITGA4ITGB7CTSS | |
| SCHEMBL3319460 | 0.91 | PPARG (0.58) | PPARGPPARAITGA4ITGB7CTSS | |
| SCHEMBL2728823 | 0.91 | PPARG (0.58) | PPARGPPARAITGA4ITGB7CTSS | |
| SCHEMBL28209015 | 0.89 | PPARG (0.52) | PPARGPPARAITGA4ITGB7CTSS | |
| SCHEMBL31213493 | 0.88 | CTSS (0.54) | PPARGPPARAITGA4ITGB7CTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107935875-B | Method for synthesizing melphalan | 兆科（广州）肿瘤药物有限公司 | 2020-07-24 | — | — | CN | claimed |
| CN-107935875-A | A kind of synthetic method of melphalan | 兆科药业（广州）有限公司 | 2018-04-20 | — | — | CN | claimed |
| US-6420424-B1 | ADMINISTERING PHENYLALANINE AMIDE DERIVATIVES (SUCH AS S-ETHYL-2-AMINO-3-(4-CHLOROPHENYL)PROPIONATE HYDROCHLORIDE) TO TREAT ALLERGIC DISORDERS, INCLUDING ASTHMA, RHINITIS, DERMATITUS, AND PRURITIS | SMITHKLINE BEECHAM CORPORATION | 2002-07-16 | — | — | US | claimed |
| CN-107935875-B | Method for synthesizing melphalan | 兆科（广州）肿瘤药物有限公司 | 2020-07-24 | — | — | CN | disclosed |
| CN-107935875-A | A kind of synthetic method of melphalan | 兆科药业（广州）有限公司 | 2018-04-20 | — | — | CN | disclosed |
| CN-101006097-B | Vla-4 antagonists | MERCK SHARP & DOHME | 2012-07-11 | — | — | CN | disclosed |
| US-7884204-B2 | such as (2S)-2-[(2,6-dichlorobenzoyl)amino]-3-[4-(4-hydroxy-1-methyl-2-oxo-1,2-dihydro-3-quinolinyl)phenyl]propionic acid, used for the teratment of inflammatory diseases, arthritis, inflammatory bowel diseases, lupus, multiple syndrome, asthma, psoriasis, allergies, diabetes and cardiovascular diseases | AJINOMOTO CO., INC. (JP) | 2011-02-08 | — | — | US | disclosed |
| US-7884204-B2 | such as (2S)-2-[(2,6-dichlorobenzoyl)amino]-3-[4-(4-hydroxy-1-methyl-2-oxo-1,2-dihydro-3-quinolinyl)phenyl]propionic acid, used for the teratment of inflammatory diseases, arthritis, inflammatory bowel diseases, lupus, multiple syndrome, asthma, psoriasis, allergies, diabetes and cardiovascular diseases | AJINOMOTO CO., INC. (JP) | 2011-02-08 | — | — | US | disclosed |
| EP-1691199-B1 | METHOD OF PREDICTING SPOT FORMATION ON THE SKIN WITH THE USE OF SPOT SITE-ACCELERATING GENES AS INDICATION AND METHOD OF SCREENING INHIBITOR FOR SPOT FORMATION ON THE SKIN | SHISEIDO CO LTD (JP) | 2009-04-01 | — | — | EP | disclosed |
| US-20090069376-A1 | VLA-4 Antagonists | MERCK SHARP & DOHME CORP. | 2009-03-12 | — | — | US | disclosed |
| US-20090069376-A1 | VLA-4 Antagonists | MERCK SHARP & DOHME CORP. | 2009-03-12 | — | — | US | disclosed |
| CN-101006097-A | VLA-4 antagonists | MERCK & CO INC (US) | 2007-07-25 | — | — | CN | disclosed |
| CN-1930147-A | VLA-4 antagonists | MERCK & CO INC (US) | 2007-03-14 | — | — | CN | disclosed |
| WO-2006115918-A2 | VLA-4 ANTAGONISTS | MERCK & CO., INC. (US) | 2006-11-02 | — | — | WO | disclosed |
| EP-1691199-A1 | METHOD OF PREDICTING SPOT FORMATION ON THE SKIN WITH THE USE OF SPOT SITE-ACCELERATING GENES AS INDICATION AND METHOD OF SCREENING INHIBITOR FOR SPOT FORMATION ON THE SKIN | SHISEIDO COMPANY LIMITED (JP) | 2006-08-16 | — | — | EP | disclosed |
| US-6420424-B1 | ADMINISTERING PHENYLALANINE AMIDE DERIVATIVES (SUCH AS S-ETHYL-2-AMINO-3-(4-CHLOROPHENYL)PROPIONATE HYDROCHLORIDE) TO TREAT ALLERGIC DISORDERS, INCLUDING ASTHMA, RHINITIS, DERMATITUS, AND PRURITIS | SMITHKLINE BEECHAM CORPORATION | 2002-07-16 | — | — | US | disclosed |
| US-6265418-B1 | ANTICOAGULANTS | UBE INDUSTRIES, LTD. (JP) | 2001-07-24 | — | — | US | disclosed |
| EP-1020467-A1 | N-ACYLAMINO ACID AMIDE COMPOUNDS AND INTERMEDIATES FOR PREPARATION THEREOF | UBE INDUSTRIES LIMITED (JP) | 2000-07-19 | — | — | EP | disclosed |
| EP-0879227-A1 | TYROSIN-DERIVATE AS ALPHA-V-INTEGRIN INHIBITORS | MERCK PATENT GmbH (DE) | 1998-11-25 | — | — | EP | disclosed |
| WO-1997023451-A1 | TYROSIN-DERIVATE AS ALPHA-V-INTEGRIN INHIBITORS | MERCK Patent Gesellschaft mit beschränkter Haftung (DE) | 1997-07-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090069376-A1 | VLA-4 Antagonists | VCAM1, SELPLG, ITGB4 | PPARG 2001/4885PPARA 366/4885ITGA4 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.